Olaparib bulk supplier for pharma manufacturers

Olaparib 100 mg, 150 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 100 mg, 150 mg

Reference Brands: Lynparza® (US & EU)

Olaparib tablets (100 mg, 150 mg) are a PARP inhibitor for ovarian, breast, prostate and pancreatic cancers with BRCA mutations or related DNA-repair defects. The originator is AstraZeneca's Lynparza. US generic entry is expected from 2027, and generic versions are already sold in some markets. Patent status differs by country, so we confirm what can lawfully be supplied to your destination before quoting.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Olaparib? List it or send an offer →

Product Description: Olaparib Tablets, sold under the brand name Lynparza®, are oral PARP inhibitors used in treating advanced ovarian, breast, pancreatic, and prostate cancers, especially in patients with BRCA mutations. Olaparib interferes with cancer cell DNA repair, enhancing cell death in tumors with deficient repair mechanisms. Available in 100 mg and 150 mg strengths, these tablets are approved in both the US and EU and manufactured under GMP-certified facilities. As a breakthrough targeted therapy, Olaparib is a valuable option for oncology-focused pharmaceutical partners seeking high-quality, globally compliant formulations for B2B supply in regulated markets.

Olaparib — third party manufacturing & bulk supply

Olaparib 100 mg, 150 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Olaparib is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Olaparib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Olaparib →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Women with BRCA-mutated or HRD-positive ovarian cancer as maintenance, early and metastatic BRCA-mutated HER2-negative breast cancer, BRCA-mutated pancreatic cancer and some prostate cancers.

The original 50 mg capsules (400 mg twice daily) and the 100/150 mg tablets (300 mg twice daily) have different bioavailability, so doses differ.

US generic entry is expected from August 2027. In other markets it depends on local patents, so we confirm before quoting.